These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 25867204)
1. Hemolytic events after the administration of lyophilized versus liquid immune globulin: an analysis of a single manufacturer's safety database. Berg R; Jacob D; Fuellenhals E Transfusion; 2015 Aug; 55(8):1847-54. PubMed ID: 25867204 [TBL] [Abstract][Full Text] [Related]
2. Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012. Berg R; Shebl A; Kimber MC; Abraham M; Schreiber GB Transfusion; 2015 Jul; 55 Suppl 2():S36-46. PubMed ID: 26174896 [TBL] [Abstract][Full Text] [Related]
3. Complementary use of passive surveillance and Mini-Sentinel to better characterize hemolysis after immune globulin. Winiecki S; Baer B; Chege W; Jankosky C; Mintz P; Baker M; Woodworth T; Nguyen M Transfusion; 2015 Jul; 55 Suppl 2():S28-35. PubMed ID: 26174895 [TBL] [Abstract][Full Text] [Related]
4. Occurrence of hemolytic reactions on the same day as immune globulin product administrations during 2008 to 2014. Sridhar G; Ekezue BF; Izurieta HS; Forshee RA; Selvam N; Mintz PD; Anderson SA; Menis MD Transfusion; 2018 Jan; 58(1):70-80. PubMed ID: 29119575 [TBL] [Abstract][Full Text] [Related]
5. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Kahwaji J; Barker E; Pepkowitz S; Klapper E; Villicana R; Peng A; Chang R; Jordan SC; Vo AA Clin J Am Soc Nephrol; 2009 Dec; 4(12):1993-7. PubMed ID: 19833910 [TBL] [Abstract][Full Text] [Related]
6. The role of isoagglutinins in intravenous immunoglobulin-related hemolysis. Bellac CL; Hottiger T; Jutzi MP; Bögli-Stuber K; Sänger M; Hanschmann KM; Keller-Stanislawski B; Funk MB Transfusion; 2015 Jul; 55 Suppl 2():S13-22. PubMed ID: 26174892 [TBL] [Abstract][Full Text] [Related]
7. Intravenous immune globulin-related hemolysis: comparing two different methods for case assessment. Taylor E; Vu D; Legare C; Keene D Transfusion; 2015 Jul; 55 Suppl 2():S23-7. PubMed ID: 26174894 [TBL] [Abstract][Full Text] [Related]
9. Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. Daniel GW; Menis M; Sridhar G; Scott D; Wallace AE; Ovanesov MV; Golding B; Anderson SA; Epstein J; Martin D; Ball R; Izurieta HS Transfusion; 2012 Oct; 52(10):2113-21. PubMed ID: 22448967 [TBL] [Abstract][Full Text] [Related]
10. A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin-mediated hemolysis. Pendergrast J; Armali C; Callum J; Cserti-Gazdewich C; Jiwajee A; Lieberman L; Lau W; Lin Y; Parmar N; Pavenski K; Riden LS; Shehata N; Willie-Ramharack K; Tomlinson G; Tong TN; Binnington B; Branch DR; Transfusion; 2021 Apr; 61(4):1053-1063. PubMed ID: 33433931 [TBL] [Abstract][Full Text] [Related]
11. Aseptic meningitis following therapy with immune globulins: a combination of product features and patient characteristics? Berg R; Fuellenhals E Transfusion; 2016 Dec; 56(12):3021-3028. PubMed ID: 27807853 [TBL] [Abstract][Full Text] [Related]
12. Pathogenesis and mechanisms of antibody-mediated hemolysis. Flegel WA Transfusion; 2015 Jul; 55 Suppl 2(0):S47-58. PubMed ID: 26174897 [TBL] [Abstract][Full Text] [Related]
13. Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports. Shebl A; Gabriel S; Van Dinther K; Hubsch A; Lawo JP; Hoefferer L; Welsh S Transfusion; 2020 Jun; 60(6):1278-1286. PubMed ID: 32410287 [TBL] [Abstract][Full Text] [Related]
14. Do immune complexes play a role in hemolytic sequelae of intravenous immune globulin? Zimring JC Transfusion; 2015 Jul; 55 Suppl 2():S86-9. PubMed ID: 26174903 [TBL] [Abstract][Full Text] [Related]
15. Specifications for anti-A and anti-B in intravenous immunoglobulin: history and rationale. Thorpe SJ Transfusion; 2015 Jul; 55 Suppl 2():S80-5. PubMed ID: 26174902 [TBL] [Abstract][Full Text] [Related]
16. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Daw Z; Padmore R; Neurath D; Cober N; Tokessy M; Desjardins D; Olberg B; Tinmouth A; Giulivi A Transfusion; 2008 Aug; 48(8):1598-601. PubMed ID: 18466176 [TBL] [Abstract][Full Text] [Related]
17. Anti-A and anti-B: what are they and where do they come from? Branch DR Transfusion; 2015 Jul; 55 Suppl 2():S74-9. PubMed ID: 26174901 [TBL] [Abstract][Full Text] [Related]
18. Effects of the manufacturing process on the anti-A isoagglutinin titers in intravenous immunoglobulin products. Romberg V; Hoefferer L; El Menyawi I Transfusion; 2015 Jul; 55 Suppl 2():S105-9. PubMed ID: 26174887 [TBL] [Abstract][Full Text] [Related]
19. The role of inflammation in intravenous immune globulin-mediated hemolysis. Pendergrast J; Willie-Ramharack K; Sampson L; Laroche V; Branch DR Transfusion; 2015 Jul; 55 Suppl 2():S65-73. PubMed ID: 26174900 [TBL] [Abstract][Full Text] [Related]
20. Immune globulins and same-day thrombotic events as recorded in a large health care database during 2008 to 2012. Sridhar G; Ekezue BF; Izurieta HS; Selvam N; Ovanesov MV; Divan HA; Liang Y; Golding B; Forshee RA; Anderson SA; Menis M Transfusion; 2014 Oct; 54(10):2553-65. PubMed ID: 24804899 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]